Abstract
Colorectal adenomas (CRA) are precursor lesions of the colon that may progress to adenocarcinomas, with patients currently categorized into risk groups by morphological features. We aimed to establish a molecular feature-based risk allocation framework towards improved patient stratification. Deep Visual Proteomics (DVP) is a novel approach that combines image-based artificial intelligence with automated microdissection and ultra-high sensitive mass spectrometry. Here we used DVP on formalin-fixed, paraffin-embedded (FFPE) CRA tissues from nine patients, immunohistologically stained for Caudal-type homeobox 2 (CDX2), a protein implicated in colorectal cancer, enabling the characterization of cellular heterogeneity within distinct tissue regions and across patients. DVP seamlessly integrated with current pathology workflows and equipment, identifying DMBT1, MARCKS and CD99 as correlated with disease recurrence history, making them potential markers of risk stratification. DVP uncovered a metabolic switch towards anaerobic glycolysis in areas of high dysplasia, which was specific for cells with high CDX2 expression. Our findings underscore the potential of spatial proteomics to refine early-stage detection and contribute to personalized patient management strategies and provided novel insights into metabolic reprogramming.
Competing Interest Statement
Matthias Mann is an indirect investor in Evosep Biosystems. The other authors declare have no conflicts of interest with the contents of this article.
Funding Statement
This work is supported financially by the Novo Nordisk Foundation (grant NNF14CC0001), the Max Planck Society and the Sawmill Owner Jeppe Juhl and Wife Ovita Juhl Memorial Foundation. Additionally, S. Kabatnik and F. Post were supported by the Novo Nordisk Foundation grant NNF20SA0035590 and NNF0069780.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The experimental design including the Deep Visual Proteomics workflow was approved by the National Committee on Health Research Ethics (j.nr. 2112779), and a waiver for obtaining informed consent was granted (as per section 10, subsection 1 of the Committee Act).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The proteomics raw data have been submitted to the ProteomeXchange Consortium through the PRIDE partner repository (https://www.ebi.ac.uk/pride/) with the identifier PXD046999. Image raw data will be provided upon request by contacting Sonja Kabatnik at sonja.kabatnik{at}cpr.ku.dk.
